Abcam’s new CRISPR-Cas9 knockout cell lines provide reproducible, single gene KOs that support the interrogation of the relationship between genotype and phenotype.
Cambridge, UK, 30th January 2020 – Abcam’s new CRISPR-Cas9 knockout (KO) cell lines provide reproducible, single gene KOs that support the interrogation of the relationship between genotype and phenotype.
Obtaining high-quality KO cell lines and lysates that match specific experimental requirements can be technically challenging and time consuming, requiring months for transfection, clone isolation and screening work. Having a reliable, ready-to-use source of KO cell lines allows researchers to confidently progress target identification and validation without the need to first establish a KO cell line.
Abcam’s newly-launched collection provides the global scientific community with a wide range of KOs in commonly used immortalized cancer cell lines such as Hela and HEK293T. With an ever- expanding range of new targets and parental cell lines, selection and ordering is as easy as buying a reagent.
All KO cell lines are Sanger sequenced to confirm knockout, and many have additional Western blot data included. A wild-type positive control cell line is also available.
Abcam’s KO cell lines deliver:
- Immediate access to pre-validated CRISPR-Cas9-engineered KO cell lines derived from Hela and HEK293T
- Supports target identification, validation and pathway discovery, antibody screening and validation, compound hit identification and validation as well as disease model development
- No in-house CRISPR-Cas9 or molecular biology expertise required, saving >3 months of KO production work
- ENDS -
Notes to Editors
About Abcam plc
As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster. Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company’s proprietary discovery platforms and world-leading, antibody expertise. By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company’s pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products. With eleven sites globally, many of Abcam’s 1,100 strong team are located in the world’s leading life science research hubs, complementing a global network of services and support.
To find out more, please visit www.abcam.com and www.abcamplc.com.
For more information please contact:
Dr Priya Kalia
External Communications Director
E: Priya.Kalia@abcam.com
